158 related articles for article (PubMed ID: 32874680)
1. Development of a Software for Treat-To-Target Strategy Implementation and Increasing Quality of Life in Patients with Inflammatory Bowel Disease.
Popa DE; Manea NC; Gheonea DI; PÎrlog MC
Curr Health Sci J; 2020; 46(2):103-110. PubMed ID: 32874680
[TBL] [Abstract][Full Text] [Related]
2. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Peyrin-Biroulet L; Sandborn W; Sands BE; Reinisch W; Bemelman W; Bryant RV; D'Haens G; Dotan I; Dubinsky M; Feagan B; Fiorino G; Gearry R; Krishnareddy S; Lakatos PL; Loftus EV; Marteau P; Munkholm P; Murdoch TB; Ordás I; Panaccione R; Riddell RH; Ruel J; Rubin DT; Samaan M; Siegel CA; Silverberg MS; Stoker J; Schreiber S; Travis S; Van Assche G; Danese S; Panes J; Bouguen G; O'Donnell S; Pariente B; Winer S; Hanauer S; Colombel JF
Am J Gastroenterol; 2015 Sep; 110(9):1324-38. PubMed ID: 26303131
[TBL] [Abstract][Full Text] [Related]
3. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
[TBL] [Abstract][Full Text] [Related]
7. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
8. Fecal Eosinophil Cationic Protein Is a Diagnostic and Predictive Biomarker in Young Adults with Inflammatory Bowel Disease.
Abedin N; Seemann T; Kleinfeld S; Ruehrup J; Röseler S; Trautwein C; Streetz K; Sellge G
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31756948
[TBL] [Abstract][Full Text] [Related]
9. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
10. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.
Juncadella A; Papamichael K; Vaughn BP; Cheifetz AS
Dig Dis Sci; 2018 Nov; 63(11):3067-3073. PubMed ID: 30006816
[TBL] [Abstract][Full Text] [Related]
11. Prediction of treatment outcome and relapse in inflammatory bowel disease.
Kato J; Yoshida T; Hiraoka S
Expert Rev Clin Immunol; 2019 Jun; 15(6):667-677. PubMed ID: 30873890
[TBL] [Abstract][Full Text] [Related]
12. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
14. Benefits and Challenges of Treat-to-Target in Inflammatory Bowel Disease.
West J; Tan K; Devi J; Macrae F; Christensen B; Segal JP
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834936
[TBL] [Abstract][Full Text] [Related]
15. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
[TBL] [Abstract][Full Text] [Related]
16. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease.
Abej E; El-Matary W; Singh H; Bernstein CN
Can J Gastroenterol Hepatol; 2016; 2016():2483261. PubMed ID: 27774443
[No Abstract] [Full Text] [Related]
17. Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature.
Darr U; Khan N
Curr Treat Options Gastroenterol; 2017 Mar; 15(1):116-125. PubMed ID: 28161818
[TBL] [Abstract][Full Text] [Related]
18. Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease.
El-Matary W; Abej E; Deora V; Singh H; Bernstein CN
Front Pediatr; 2017; 5():7. PubMed ID: 28180127
[TBL] [Abstract][Full Text] [Related]
19. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
20. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
